肺癌骨转移是晚期肺癌患者死亡及生活质量恶化的关键因素,约20%~60%的患者病程中会发生骨转移,从而引发骨痛、骨折等高发骨骼相关事件。现代医学治疗手段存在耐药性、肾损伤及经济负担等局限。中医药通过多途径干预展现出独特优势:内治...肺癌骨转移是晚期肺癌患者死亡及生活质量恶化的关键因素,约20%~60%的患者病程中会发生骨转移,从而引发骨痛、骨折等高发骨骼相关事件。现代医学治疗手段存在耐药性、肾损伤及经济负担等局限。中医药通过多途径干预展现出独特优势:内治法中,经典方剂联合西药可显著缓解疼痛、降低肿瘤标志物,单味药提取物通过诱导癌细胞凋亡抑制肿瘤;外治法如温经止痛方穴位外敷可协同增强镇痛效果;针灸调节疼痛相关血清因子,减少阿片类药物用量及副作用。研究证实,中医药通过调控相关信号通路、改善骨代谢及免疫功能,联合治疗使骨相关事件减少。本研究拟推动中医药与现代医学融合,为优化治疗方案提供循证依据。Bone metastasis of lung cancer is a key factor in the death and deterioration of quality of life of patients with advanced lung cancer. About 20%~60% of patients have bone metastasis during the course of the disease, causing high incidence of bone-related events such as bone pain and fracture. Modern medical methods have limitations such as drug resistance, renal injury and economic burden. Traditional Chinese medicine shows unique advantages through multi-channel intervention: in the internal treatment, classical prescriptions combined with western medicine can significantly relieve pain and reduce tumor markers, and single drug extracts inhibit tumors by inducing apoptosis of cancer cells;external treatment such as acupoint external application of Wenjing Zhitong prescription can synergistically enhance the analgesic effect;acupuncture regulates pain-related serum factors and reduces opioid dosage and side effects. Studies have confirmed that traditional Chinese medicine can reduce bone-related events by regulating related signaling pathways, improving bone metabolism and immune function, and combined treatment. This study intends to promote the integration of traditional Chinese medicine and modern medicine, and provide evidence-based basis for optimizing the treatment plan.展开更多
原发性肺癌是我国最常见的恶性肿瘤之一[1-4]。2012年中国肿瘤登记年报显示：肺癌发病率和死亡率居全国众癌之首，且其发病隐匿，确诊时约50%为晚期（IV期），骨转移是主要的血行转移部位之一[5]。随着治疗方法和技术的进步，晚期肺癌...原发性肺癌是我国最常见的恶性肿瘤之一[1-4]。2012年中国肿瘤登记年报显示：肺癌发病率和死亡率居全国众癌之首，且其发病隐匿，确诊时约50%为晚期（IV期），骨转移是主要的血行转移部位之一[5]。随着治疗方法和技术的进步，晚期肺癌患者的中位生存时间逐渐延长至1年左右[6]。患者生存获益的同时，发生骨转移及骨相关事件（Skeletal Related Events, SRE）的风险亦随之增高[7-10]。展开更多
肺癌是临床最常见恶性肿瘤之一,骨转移的发生率为30%～40%,骨转移发生后,患者出现的骨痛及一系列骨相关事件（skeletal related events,SREs）是降低患者生活质量和影响患者生存的重要因素。研究肺癌骨转移的发生机制,是寻找有效抑制或...肺癌是临床最常见恶性肿瘤之一,骨转移的发生率为30%～40%,骨转移发生后,患者出现的骨痛及一系列骨相关事件（skeletal related events,SREs）是降低患者生活质量和影响患者生存的重要因素。研究肺癌骨转移的发生机制,是寻找有效抑制或治疗骨转移方法的理论关键,本文就肺癌骨转移的相关分子生物学进展综述如下。1肺癌骨转移的发生及形成机制1.1肺癌细胞的播散肿瘤细胞从原发肿瘤中脱离出来并进入循环系统是转移形成的第一步。促进肿瘤细胞脱离的因素可分为两类：肿瘤局部基质的改变及肿瘤细胞自身的改变。展开更多
文摘肺癌骨转移是晚期肺癌患者死亡及生活质量恶化的关键因素,约20%~60%的患者病程中会发生骨转移,从而引发骨痛、骨折等高发骨骼相关事件。现代医学治疗手段存在耐药性、肾损伤及经济负担等局限。中医药通过多途径干预展现出独特优势:内治法中,经典方剂联合西药可显著缓解疼痛、降低肿瘤标志物,单味药提取物通过诱导癌细胞凋亡抑制肿瘤;外治法如温经止痛方穴位外敷可协同增强镇痛效果;针灸调节疼痛相关血清因子,减少阿片类药物用量及副作用。研究证实,中医药通过调控相关信号通路、改善骨代谢及免疫功能,联合治疗使骨相关事件减少。本研究拟推动中医药与现代医学融合,为优化治疗方案提供循证依据。Bone metastasis of lung cancer is a key factor in the death and deterioration of quality of life of patients with advanced lung cancer. About 20%~60% of patients have bone metastasis during the course of the disease, causing high incidence of bone-related events such as bone pain and fracture. Modern medical methods have limitations such as drug resistance, renal injury and economic burden. Traditional Chinese medicine shows unique advantages through multi-channel intervention: in the internal treatment, classical prescriptions combined with western medicine can significantly relieve pain and reduce tumor markers, and single drug extracts inhibit tumors by inducing apoptosis of cancer cells;external treatment such as acupoint external application of Wenjing Zhitong prescription can synergistically enhance the analgesic effect;acupuncture regulates pain-related serum factors and reduces opioid dosage and side effects. Studies have confirmed that traditional Chinese medicine can reduce bone-related events by regulating related signaling pathways, improving bone metabolism and immune function, and combined treatment. This study intends to promote the integration of traditional Chinese medicine and modern medicine, and provide evidence-based basis for optimizing the treatment plan.
文摘原发性肺癌是我国最常见的恶性肿瘤之一[1-4]。2012年中国肿瘤登记年报显示：肺癌发病率和死亡率居全国众癌之首，且其发病隐匿，确诊时约50%为晚期（IV期），骨转移是主要的血行转移部位之一[5]。随着治疗方法和技术的进步，晚期肺癌患者的中位生存时间逐渐延长至1年左右[6]。患者生存获益的同时，发生骨转移及骨相关事件（Skeletal Related Events, SRE）的风险亦随之增高[7-10]。
文摘肺癌是临床最常见恶性肿瘤之一,骨转移的发生率为30%～40%,骨转移发生后,患者出现的骨痛及一系列骨相关事件（skeletal related events,SREs）是降低患者生活质量和影响患者生存的重要因素。研究肺癌骨转移的发生机制,是寻找有效抑制或治疗骨转移方法的理论关键,本文就肺癌骨转移的相关分子生物学进展综述如下。1肺癌骨转移的发生及形成机制1.1肺癌细胞的播散肿瘤细胞从原发肿瘤中脱离出来并进入循环系统是转移形成的第一步。促进肿瘤细胞脱离的因素可分为两类：肿瘤局部基质的改变及肿瘤细胞自身的改变。
